The Latest Anticoagulation Journal Articles

Please login or register to bookmark this article feed
Bookmark this %label%

Keep up to date with the latest in anticoagulation. Check out the latest anticoagulation articles from leading medical journals in a single view, helping you discover relevant articles quickly and easily

  • Anticoagulant therapy for splanchnic vein thrombosis: A systematic review and meta-analysis.
    Treatment of splanchnic vein thrombosis (SVT) is challenging and evidence to guide therapeutic decisions remains scarce. The objective of this systematic review and meta-analysis was to determine the efficacy and safety of anticoagulant therapy for SVT. MEDLINE, EMBASE, and Clinicaltrial.gov were searched from inception up to December 2019 without language restrictions to include observational studies […]
  • How I treat anticoagulant-refractory thrombotic antiphospholipid syndrome.
    The standard treatment of thrombotic antiphospholipid syndrome (APS) is lifelong oral anticoagulation with a vitamin K antagonist (VKA), generally warfarin. A minority of APS patients re-thrombose despite seemingly adequate anticoagulation. These patients are deemed anticoagulant-refractory. The management of anticoagulant-refractory APS is largely empirical and extrapolated from other clinically similar situations. Further options include increased VKA […]
  • Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation.
    The effect of single as compared with dual antiplatelet treatment on bleeding and thromboembolic events after transcatheter aortic-valve implantation (TAVI) in patients who do not have an indication for long-term anticoagulation has not been well studied.In a randomized, controlled trial, we assigned a subgroup of patients who were undergoing TAVI and did not have an […]
  • How I treat venous thromboembolism in pregnancy.
    Of 1,000 pregnant women, one to two will experience venous thromboembolism (VTE) during pregnancy or the postpartum period. Pulmonary embolism (PE) is a leading cause of maternal mortality and deep vein thrombosis (DVT) leads to maternal morbidity and may diminish quality of life due to post-thrombotic syndrome during the rest of a woman’s life. Despite […]
  • How I treat unexplained arterial thrombosis.
    Most arterial thrombotic events have a clear atherosclerotic or cardioembolic etiology, but hematologists are frequently asked to assist in the diagnosis and management of a patient with a non-atherosclerotic and non-cardioembolic arterial event, referred to herein as an unexplained arterial thrombosis. Because there is an assorted list of factors that can precipitate an arterial event, […]
  • COVID and Coagulation: Bleeding and Thrombotic Manifestations of SARS-CoV2 Infection.
    Patients with coronavirus disease 2019 (COVID-19) have elevated D-dimer levels. Early reports describe high venous thromboembolism (VTE) and disseminated intravascular coagulation (DIC) rates, but data are limited. This multicenter, retrospective study described the rate and severity of hemostatic and thrombotic complications of 400 hospital-admitted COVID-19 patients (144 critically ill) primarily receiving standard-dose prophylactic anticoagulation. Coagulation […]
  • Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis.
    Direct oral anticoagulants (DOACs) are an emerging treatment option for cancer patients with acute venous thromboembolism (VTE), but studies have reported inconsistent results. This systematic review and meta-analysis compared the efficacy and safety of DOACs and low-molecular-weight heparins (LMWH) in these patients. MEDLINE, Embase, CENTRAL, and conference proceedings were searched to identify relevant randomized controlled […]
  • A cell-based high-throughput screen identifies drugs that cause bleeding disorders by off-targeting the vitamin K cycle.
    Drug-induced bleeding disorders contribute to substantial morbidity and mortality. Antithrombotic agents that cause unintended bleeding with obvious reasons are relatively easy to control. However, the mechanisms of most drug-induced bleeding disorders are poorly understood which makes intervention more difficult. As most bleeding disorders are associated with the dysfunction of coagulation factors, we adapted our recently […]
  • Ecarin based coagulation testing.
    Ecarin is derived from venom of Echis carinatus and will activate prothrombin into meizothrombin which will then cleave fibrinogen to result in clot formation. Ecarin based testing has been described for decades, but these assays were typically restricted to reference or speciality coagulation laboratories. This test was initially described for the assessment of direct thrombin […]
  • COVID-19 and its implications for thrombosis and anticoagulation.
    The SARS-CoV-2 coronavirus (COVID-19) induced infection can be associated with a coagulopathy, findings consistent with infection induced inflammatory changes as observed in patients with disseminated intravascular coagulopathy (DIC). The lack of prior immunity to COVID-19 has resulted in large numbers of infected patients across the globe and uncertainty regarding management of the complications that arise […]
  • COVID-19 Coagulopathy in Caucasian patients.
    Although the pathophysiology underlying severe COVID-19 remains poorly understood, accumulating data suggest that a lung-centric coagulopathy may play an important role. Elevated D-dimer levels which correlated inversely with overall survival were recently reported in Chinese cohort studies. Critically however, ethnicity has major effects on thrombotic risk, with a 3-4 fold lower risk in Chinese compared […]
  • Alternative assays to dRVVT and aPTT for lupus anticoagulant detection.
    Lupus anticoagulants (LA) are heterogeneous antibodies and no single assay will detect every LA. Consequently, testing is commonly undertaken with both dilute Russell’s viper venom time (dRVVT) and LA-responsive activated partial thromboplastin time (aPTT) to maximise detection rates. Although a huge body of evidence attests to the diagnostic utility of these assays, they have limitations […]
  • Changes in Blood Coagulation in Patients with Severe Coronavirus Disease 2019 (COVID-19): a Meta-Analysis.
    Coronavirus disease 2019 (COVID-19) is widely spread and poses a critical threat to global health (Zhang et al). Prominent changes in coagulation function in severe patients of COVID-19 have been reported in a recent study (Han, et al 2020). Therefore, we conducted this quantitative meta-analysis to explore the difference in blood coagulation parameters between severe […]
  • Thromboembolic risk and anticoagulant therapy in COVID-19 patients: Emerging evidence and call for action.
    Emerging evidence shows that severe coronavirus disease 2019 (COVID-19) can be complicated with coagulopathy namely disseminated intravascular coagulation, which has a rather pro-thrombotic character with high risk of venous thromboembolism. The incidence of venous thromboembolism among COVID-19 patients in Intensive Care Unit appears to be somewhat higher compared to that reported in other studies including […]
  • Platelet protein S limits venous but not arterial thrombosis propensity by controlling coagulation in the thrombus.
    Anticoagulant protein S (PS) in platelets (PSplt) resembles plasma PS and is released upon platelet activation; but its role in thrombosis has not been elucidated. Here we report that inactivation of PSplt expression using the Pf4-Cre transgene (Pros1lox/loxPf4-Cre+) in mice promotes thrombus propensity in the vena cava where shear rates are low, but not in […]
  • Treatment of Upper Extremity Deep Vein Thrombosis with Apixaban and Rivaroxaban.
    Randomized controlled trials leading to the approval of apixaban and rivaroxaban for venous thromboembolism (VTE) did not include patients with upper extremity deep vein thrombosis (UE-DVT). We sought to evaluate the safety and effectiveness of rivaroxaban and apixaban for the treatment of acute UE-DVT. Consecutive patients with VTE enrolled into the Mayo Clinic VTE Registry, […]
  • Anticoagulation with or without Clopidogrel after Transcatheter Aortic-Valve Implantation.
    The roles of anticoagulation alone or with an antiplatelet agent after transcatheter aortic-valve implantation (TAVI) have not been well studied.We performed a randomized trial of clopidogrel in patients undergoing TAVI who were receiving oral anticoagulation for appropriate indications. Patients were assigned before TAVI in a 1:1 ratio not to receive clopidogrel or to receive clopidogrel […]
  • The role of type 1 interferons in Gram-negative bacteria-induced coagulation.
    Bacterial infection not only stimulates innate immune responses but also activates the coagulation cascades. Over-activation of the coagulation system in bacterial sepsis leads to disseminated intravascular coagulation (DIC), a life-threatening condition. However, the mechanisms by which bacterial infection activates the coagulation cascade are not fully understood. Here we show that type 1 interferons (IFNs), widely […]
  • Diagnosis of suspected recurrent ipsilateral deep vein thrombosis with magnetic resonance direct thrombus imaging.
    The diagnosis of recurrent ipsilateral deep vein thrombosis (DVT) is challenging because persistent intravascular abnormalities after previous DVT often hinder a diagnosis by compression ultrasonography. Magnetic resonance direct thrombus imaging (MRDTI), a technique without intravenous contrast and with a 10-minute acquisition time, has been shown to accurately distinguish acute recurrent DVT from chronic thrombotic remains. […]
  • Seronegative antiphospholipid syndrome: refining the value of non-criteria antibodies for the diagnosis and clinical management.
    Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by arterial and venous thrombotic manifestations and/or pregnancy-related complications in patients with persistently high antiphospholipid antibodies (aPL), the most common being represented by anticardiolipin antibodies (aCL), anti-beta 2 glycoprotein-I (aβ2GPI) and lupus anticoagulant (LAC). A growing number of studies showed that in some cases patients may […]
  • CRISPR/Cas9-mediated knockin of human factor IX into swine factor IX locus effectively alleviates bleeding in hemophilia B pigs.
    Hemophilia B is an X-linked recessive bleeding disorder caused by abnormalities in the coagulation factor IX gene. Without prophylactic treatment, patients experience frequent spontaneous bleeding episodes. Well-characterized animal models are valuable for determining the pathobiology of the disease and testing novel therapeutic innovations. Here, we generated a porcine model of hemophilia B using a combination […]
  • Alternative activation of human macrophages enhances tissue factor expression and production of extracellular vesicles.
    Macrophages are versatile cells that can be polarized by the tissue environment to fulfill required needs. Proinflammatory polarization is associated with increased tissue degradation and propagation of inflammation whereas alternative polarization within a Th2 cytokine environment is associated with wound healing and angiogenesis. To understand if polarization of macrophages can lead to a procoagulant macrophage […]
  • How I Treat Obese Patients with Oral Anticoagulants.
    Obesity has become a major threat to health worldwide. The prevalence of obesity is rapidly increasing, so much so that the World Health Organization has declared obesity as global epidemic. Obesity is associated with multiple health problems, including venous thromboembolism and atrial fibrillation, both of which are treated with anticoagulation. However, obesity and treatments for […]
  • Thrombin-mediated activation of PAR-1 contributes to microvascular stasis in mouse models of sickle cell disease.
    Vaso-occlusive crisis (VOC) is the primary cause of morbidity and hospitalization in sickle cell disease (SCD). However, only three therapies (hydroxyurea, L-glutamine, and crizanlizumab) are currently approved in SCD. These agents limit the duration, severity, and frequency of crises. Activation of coagulation is a hallmark of SCD. Studies in animal models of SCD have shown […]
  • Protein C activator AB002 rapidly interrupts thrombus development in baboons and appears safe in a first-in-human trial.
    While thrombin is a key enzyme in the coagulation cascade and is required for both normal hemostasis and pathologic thrombogenesis, it also participates in its own negative feedback via activation of protein C, which down-regulates thrombin generation by enzymatically inactivating factors Va and VIIIa. Our group and others have previously shown that thrombin’s procoagulant and […]
  • Red Blood Cell Microvesicles Activate The Contact System Leading To Factor IX Activation Via Two Independent Pathways.
    Storage lesion-induced red cell-derived microvesicles (RBC-MVs) propagate coagulation by supporting the assembly of the prothrombinase complex. It has also been reported that RBC-MVs initiate coagulation via the intrinsic pathway. To elucidate the mechanism(s) of RBC-MV-induced coagulation activation, the ability of storage lesion-induced RBC-MVs to activate each zymogen of the intrinsic pathway was assessed in a […]
  • Acetylsalicylic acid (ASA) inhibits intravascular coagulation during S. aureus-induced sepsis in mice.
    Anti-platelet therapies have been proposed for the treatment of sepsis, a syndrome resulting from a dysregulated immune response and inappropriate activation of coagulation. Acetylsalicylic acid (ASA) may serve as a potential therapeutic strategy to prevent infection-induced coagulopathy and associated tissue damage. Using intravital microscopy, we found that S. aureus infection induced neutrophil recruitment, platelet aggregation […]
  • How I assess and manage the risk of bleeding during treatment of patients with venous thromboembolism.
    For patients with venous thromboembolism (VTE), prediction of bleeding is relevant throughout the course of treatment, although the means and goal of this prediction differ between the subsequent stages of treatment: treatment initiation, hospital discharge, 3-month follow-up and long term follow-up. Even in the absence of fully established risk prediction schemes and outcome studies using […]
  • Novel Antithrombotic Strategies for Treatment of Venous Thromboembolism.
    Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), is the third most common cause of vascular death after heart attack and stroke. Anticoagulation therapy is the cornerstone of VTE treatment. Despite such therapy, up to 50% of DVT patients develop post-thrombotic syndrome and up to 4% of PE patients develop […]
  • Treatment of unusual thrombotic manifestations.
    Venous thrombosis rarely occurs at unusual sites such as cerebral, splanchnic, upper extremity, renal, ovarian or retinal veins. Clinical features, symptoms and risk factors of rare thrombotic manifestations are heterogeneous and in large part differ from those typical of the commonest venous thrombosis at the lower extremities. Also the therapeutic approach varies widely according to […]
  • Managing Thromboembolic Risk in Patients with Hereditary and Acquired Thrombophilias.
    While we are now able to diagnose inherited thrombophilias in a substantial number of patients with venous thromboembolism (VTE), the initial hope that their presence would inform recurrence risk and thus decisions on anticoagulation duration has largely been disappointing. Indeed, the presence or absence of transient provoking risk factors has proven to be the most […]
  • ACUTE TREATMENT OF VENOUS THROMBOEMBOLISM.
    All patients with venous thromboembolism should receive anticoagulant treatment in the absence of absolute contraindications. Initial anticoagulant treatment is crucial to reduce mortality, prevent early recurrences and improve long-term outcome. Treatment and patient disposition should be tailored on the severity of clinical presentation, on comorbidities and on the potential to receive appropriate care in the […]
  • Long-term treatment of venous thromboembolism.
    The most important decision in the long-term treatment of VTE is how long to anticoagulate. VTE provoked by a reversible risk factor, or a first unprovoked isolated distal DVT, generally should be treated for 3 months. VTE provoked by a persistent or progressive risk factor (eg, cancer), or a second unprovoked proximal DVT or PE, […]
  • Treatment of venous thromboembolism in pediatric patients.
    Venous thromboembolism (VTE) is rare in healthy children,but an increasing problem in children with underlying medical conditions. Pediatric VTE encompasses a highly heterogenous population, with variation in age, thrombosis location and underlying medical co-morbidities. Evidence from pediatric clinical trials to guide treatment of VTE is lacking so treatment is often extrapolated from adult trials and […]
  • Activated protein C anticoagulant activity is enhanced by skeletal muscle myosin.
    Click here to read the full article @ Haematologica
  • Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS.
    The antiphospholipid syndrome (APS) is characterized by thrombosis and/or pregnancy morbidity in the presence of antiphospholipid antibodies including anti-beta-2-glycoprotein-I (anti-β2GPI) that are considered central to APS pathogenesis. Based on animal studies showing a role of complement in APS-related clinical events, we used the modified Ham assay (complement-dependent cell killing) and cell-surface deposition of C5b-9 to […]
  • Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children.
    This open-label, single-arm, prospective cohort trial is the first phase 3 safety study to describe outcomes in children treated with dabigatran etexilate for secondary venous thromboembolism (VTE) prevention. Eligible children aged 12 to <18 years (age stratum 1), 2 to <12 years (stratum 2), and >3 months to <2 years (stratum 3) had an objectively […]
  • TFPI blockade: removing coagulation’s brakes.
    Click here to read the full article @ Blood
  • From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms.
    Thrombotic and hemorrhagic complications are prevalent in patients with essential thrombocythemia, polycythemia vera, and myelofibrosis. Given the impact on morbidity and mortality, reducing the risk of thrombosis and/or hemorrhage is a major therapeutic goal. Historically, patients have been risk stratified on the basis of traditional factors, such as advanced age and thrombosis history. However, multiple […]
  • Reduced Leaflet Motion after Transcatheter Aortic-Valve Replacement.
    Subclinical leaflet thickening and reduced leaflet motion of bioprosthetic aortic valves have been documented by four-dimensional computed tomography (CT). Whether anticoagulation can reduce these phenomena after transcatheter aortic-valve replacement (TAVR) is not known.In a substudy of a large randomized trial, we randomly assigned patients who had undergone successful TAVR and who did not have an […]
  • A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement.
    Whether the direct factor Xa inhibitor rivaroxaban can prevent thromboembolic events after transcatheter aortic-valve replacement (TAVR) is unclear.We randomly assigned 1644 patients without an established indication for oral anticoagulation after successful TAVR to receive rivaroxaban at a dose of 10 mg daily (with aspirin at a dose of 75 to 100 mg daily for the […]
  • Splanchnic Vein Thromboses associated with Myeloproliferative Neoplasms: an international, retrospective study on 518 cases.
    Myeloproliferative Neoplasms (MPN) course can be complicated by thrombosis involving unusual sites as the splanchnic veins (SVT). Their management is challenging, given their composite vascular risk. We performed a retrospective, cohort study in the framework of the International Working Group for MPN Research and Treatment (IWG-MRT), and AIRC-Gruppo Italiano Malattie Mieloproliferative (AGIMM). 518 MPN-SVT cases […]
  • Rare variants lowering the levels of coagulation factor X are protective against ischemic heart disease.
    Click here to read the full article @ Haematologica
  • A mutated factor X activatable by thrombin corrects bleedings in vivo in a rabbit model of antibody-induced hemophilia A.
    Rendering coagulation factor X sensitive to thrombin was proposed as a strategy that can bypass the need for factor VIII. In this paper, this non-replacement strategy was evaluated in vitro and in vivo in its ability to correct factor VIII but also factor IX, X and XI deficiencies. A novel modified factor X, named Actiten, […]
  • Coagulation mixing studies: utility, algorithmic strategies and limitations for lupus anticoagulant testing or follow up of abnormal coagulation tests.
    Coagulation testing underpins the investigation of hemostasis and/or monitoring of anticoagulation therapy for prevention and/or treatment of thrombosis related pathology. Assessment of coagulation results requires comparison against a normal reference range or interval (NRR/NRI). Results flagged as ‘abnormal’ (i.e., above the NRR/NRI for patients not on anticoagulant therapy), typically require further evaluation, for example by […]
  • Vitamin K-dependent carboxylation of coagulation factors: insights from a cell-based functional study.
    Abstract: Vitamin K-dependent carboxylation is a posttranslational modification essential for the biological function of coagulation factors. Defects in carboxylation are mainly associated with bleeding disorders. With the discovery of new vitamin K-dependent proteins, the importance of carboxylation now encompasses vascular calcification, bone metabolism, and other important physiological processes. Our current knowledge of carboxylation, however, comes […]
  • Association of Surgical Hematoma Evacuation vs Conservative Treatment With Functional Outcome in Patients With Cerebellar Intracerebral Hemorrhage.
    Abstract: The association of surgical hematoma evacuation with clinical outcomes in patients with cerebellar intracerebral hemorrhage (ICH) has not been established.To determine the association of surgical hematoma evacuation with clinical outcomes in cerebellar ICH.Individual participant data (IPD) meta-analysis of 4 observational ICH studies incorporating 6580 patients treated at 64 hospitals across the United States and […]
  • Safety of using direct oral anticoagulants in the diagnostic workup of outpatients with suspicion of acute venous thromboembolism.
    Abstract: Click here to read full article on original source website
  • Circulating Levels of Biomarkers of Cerebral Injury in Patients with Atrial Fibrillation.
    Abstract: Atrial fibrillation (AF) is a source of altered brain perfusion and ischemia, potentially leading to cerebral injury and blood brain barrier (BBB) disruption, which may result in the permeation of neurospecific molecules into the bloodstream. We retrospectively analyzed circulating levels of biomarkers of cerebral injury: Astrocyte-specific glial acidic fibrillary protein (GFAP), calcium-binding protein B […]
  • Evaluation of Time to Therapeutic Anticoagulation and Associated Outcomes in Critically Ill, Obese Patients With Pulmonary Embolism Receiving Unfractionated Heparin.
    Abstract: Delays in time to therapeutic activated partial thromboplastin time (aPTT) have been associated with poor outcomes in patients with acute pulmonary embolism (PE).To investigate the relationship between time to therapeutic anticoagulation and in-hospital mortality in critically ill, obese patients with acute PE.This study examined 204 critically ill patients with a body mass index (BMI) […]
  • Female sex as a risk factor for ischaemic stroke varies with age in patients with atrial fibrillation.
    Abstract: Female sex is an inconsistent ischaemic stroke risk factor in patients with atrial fibrillation (AF). We hypothesised that the ischaemic stroke risk varies with age among women compared with men.We retrieved the patients with newly diagnosed AF during 2001-2013 from Taiwan’s National Health Insurance Research Database. Patients with missing information, age 75 years group […]
  • Nation-Wide Use of Periprocedural Bridging Anticoagulation in Patients With Atrial Fibrillation.
    Abstract: The randomized, controlled BRIDGE trial established a lack of efficacy for use of bridging anticoagulation in warfarin-treated patients who underwent surgical procedures. A large nation-wide insurance claims database was used to perform a retrospective interrupted time series cohort study of adult patients with atrial fibrillation treated with warfarin who underwent surgical procedures. Patients were […]
  • Oral Anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1.
    Abstract: Abstract empty Click here to read full article on original source website
  • Stroke and thromboembolism prevention in atrial fibrillation.
    Abstract: Prevention of stroke and systemic thromboembolism remains the cornerstone for management of atrial fibrillation (AF) and flutter. Multiple risk assessment models for stroke and systemic thromboembolism are currently available. The score, with its known limitations, remains as the recommended risk stratification tool in most major guidelines. Once at-risk patients are identified, vitamin K antagonists […]
  • Anticoagulation for Subsegmental Pulmonary Embolism.
    Abstract: Abstract empty Click here to read full article on original source website
  • Anticoagulation and anaemia: old opponents from the era of VKA?
    Abstract: Abstract empty Click here to read full article on original source website
  • Estimating individual lifetime benefit and bleeding risk of adding oral anticoagulation to aspirin for patients with stable cardiovascular disease: directions from COMPASS?
    Abstract: Abstract empty Click here to read full article on original source website
  • Secondary stroke prevention: a population-based cohort study on anticoagulation and antiplatelet treatments, and the risk of death or recurrence.
    Abstract: Using claims databases of a public healthcare program (Quebec) for the years 2010 – 2013, we conducted a cohort study of acute ischemic stroke (AIS) patients to describe secondary prevention treatments and determine how they stood against practice guidelines. We compared the risk of death or AIS recurrence over one year in patients treated […]
  • Impact of Multidisciplinary Pulmonary Embolism Response Team Availability on Management and Outcomes.
    Abstract: Treatment strategies for complex patients with pulmonary embolism (PE) are often debated given patient heterogeneity, multitude of available treatment modalities, and lack of consensus guidelines. Although multidisciplinary Pulmonary Embolism Response Teams (PERT) are emerging to address this lack of consensus, their impact on patient outcomes is not entirely clear. This analysis was conducted to […]
  • Characteristics and Outcomes of Atrial Fibrillation in Patients With Thyroid Disease (from the ARISTOTLE Trial).
    Abstract: Whether patients with atrial fibrillation (AF) and thyroid disease are clinically distinct from those with AF and no thyroid disease is unknown. Furthermore, the effectiveness of anticoagulation for prevention of AF-related thromboembolic events in patients with thyroid disease has not been adequately studied. Patients enrolled in the Apixaban for Reduction in Stroke and Other […]